News Update: Protalix (PLX) Gets Prescription Drug User Fee Act Action Date for Taliglucerase
Автор: TradeTheTrend
Загружено: 2010-07-12
Просмотров: 498
Описание:
Protalix BioTherapeutics Gets Prescription Drug User Fee Act Action Date for Taliglucerase - Stock Likely to See Pre-Bell Interest
Jul 12, 2010 -- Protalix BioTherapeutics (PLX) announced its New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Companies: Protalix BioTherapeutics, Inc.
Price: 6.32 Price Change: 0 Percent Change: 0
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: